# EDGAR Filing Document

**Accession Number:** 0001598646
**File Stem:** 0001193125-25-331086
**Filing Date:** 2025-12
**Character Count:** 22483
**Document Hash:** e9badea4cb98a3f7c3afa6ead9086dc6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-331086.hdr.sgml**: 20251223

**ACCESSION NUMBER**: 0001193125-25-331086

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251223

**DATE AS OF CHANGE**: 20251223

**EFFECTIVENESS DATE**: 20251223

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Minerva Neurosciences, Inc.
- **CENTRAL INDEX KEY:** 0001598646
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 260784194
- **STATE OF INCORPORATION:** MA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292422
- **FILM NUMBER:** 251601407

**BUSINESS ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803
- **BUSINESS PHONE:** 617-600-7373

**MAIL ADDRESS:**
- **STREET 1:** 1500 DISTRICT AVENUE
- **CITY:** BURLINGTON
- **STATE:** MA
- **ZIP:** 01803

**As filed with the U.S. Securities and Exchange Commission on December 23, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## Minerva Neurosciences, Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **26-0784194** |
| **(State or other jurisdiction of**<br> **Incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **1500 District Avenue**<br> **Burlington, MA** | **01803** |
| **(Address of principal executive offices)** | **(Zip code)** |

---

**Minerva Neurosciences, Inc. Amended and Restated 2013 Equity Incentive Plan** 

**(Full title of the plan)** 

**Remy Luthringer, Ph.D.** 

**Chief Executive Officer** 

**1500 District Avenue** 

**Burlington, MA 01803** 

**(Name and address of agent for service)** 

**(617) 600-7373** 

**(Telephone number, including area code, of agent for service)** 

***Copies to:***

**Marc Recht** 

**Ryan Sansom** 

**Cooley LLP** 

**500 Boylston Street, 14th Floor** 

**Boston, MA 02116** 

**(617) 937-2300** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same benefit plan is effective.

The Registrant previously registered shares of its Common Stock for issuance under the Plan under Registration Statements on Form S-8 filed with the Securities and Exchange Commission on September 15, 2014 ([File No. 333-198753](http://www.sec.gov/Archives/edgar/data/1598646/000110465914066346/a14-20755_1s8.htm)), April 30, 2015 ([File No. 333-203738](http://www.sec.gov/Archives/edgar/data/1598646/000119312515158672/d913241ds8.htm)), March 14, 2016 ([File No. 333-210147](http://www.sec.gov/Archives/edgar/data/1598646/000119312516502248/d150946ds8.htm)), March 13, 2017 ([File No. 333-216637](http://www.sec.gov/Archives/edgar/data/1598646/000119312517079458/d549899ds8.htm)), March 12, 2018 ([File No. 333-223593](http://www.sec.gov/Archives/edgar/data/1598646/000119312518079294/d509396ds8.htm)), June 15, 2018 ([File No. 333-225672](http://www.sec.gov/Archives/edgar/data/1598646/000119312518194554/d610260ds8.htm)) and August 7, 2020 ([File No. 333-242460](http://www.sec.gov/Archives/edgar/data/1598646/000119312520213669/d70016ds8.htm)) (each, a "Prior Registration Statement"). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced above.

------

**PART II** 

**ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE** 

The following documents filed by the Registrant with the Commission and the Prior Registration States are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000095017025026055/nerv-20241231.htm) for the fiscal year ended December 31, 2024, filed with the Commission on February 
25, 2025 and on [Form 10-K/A](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525087311/d862690d10ka.htm) on April 
21, 2025 and on [Form 10-K/A](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525100977/d90024d10ka.htm) on April 29, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2025, June 30, 2025 and September 
30, 2025, filed with the Commission on [May 13, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000095017025069780/nerv-20250331.htm) , [August 14, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000095017025108840/nerv-20250630.htm) , and [November 5, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525265685/nerv-20250930.htm) , respectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Registrant's Current Reports on Form 8-K filed with the
Commission on [January 13, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525005042/d906093d8k.htm) ; [March 19, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525057901/d841978d8k.htm) ; [October 22, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525245552/d28380d8k.htm) ; [November 19, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001598646/000119312525287048/d48648d8k.htm) ; and [December 22, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1598646/000119312525328715/d16725d8k.htm) , to the extent the information in such reports is filed and not furnished;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The information specifically incorporated by reference into the Registrant's Annual Report on Form 10-K for the fiscal year ended December 
31, 2024 from the Registrant's Definitive Proxy Statement on [Schedule 14A](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1598646/000119312525293674/d925225ddef14a.htm) filed with the Commission on
November 24, 2025, to the extent the information therein is filed and not furnished; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The description of the Registrant's Common Stock, which is contained in the Registrant's Registration
Statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1598646/000110465914047783/a14-5380_98a12b.htm) filed with the Commission on June 23, 2014, including any
amendment or report filed for the purpose of updating such description, including the description of capital stock contained in the Registrant's registration statement on [Form S-3](http://www.sec.gov/Archives/edgar/data/1598646/000119312525330849/d73753ds3.htm) , filed with the Commission on December 23, 2025.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**ITEM 8. EXHIBITS** 

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Exhibit<br>Number** | **Description** | **Schedule<br>Form** | **File<br>Number** | **Exhibit** | **Filing Date** |
| 4.1 | [Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000104746914005459/a2219972zex-3_1.htm) | S-1/A | 333-19516 | 3.1 | June 10, 2014 |
| 4.2 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000119312522176540/d314076dex31.htm) | 8-K | 001-36517 | 3.1 | June 17, 2022 |
| 4.3 | [Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000119312525330849/d73753dex33.htm) | S-3 | 333-292410 | 3.3 | December 23, 2025 |
| 4.4 | [Amended and Restated Bylaws of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000156459019039496/nerv-ex32_112.htm) | 10-Q | 001-36517 | 3.2 | November 4, 2019 |

---

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 4.5 | [Form of Common Stock Certificate of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000104746914005459/a2219972zex-4_1.htm) | S-1/A | 333-195169 | 4.1 | June 10, 2014 |
| 5.1\* | [Opinion of Cooley LLP.](d84517dex51.htm) |  |  |  |  |
| 23.1\* | [Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.](d84517dex231.htm) |  |  |  |  |
| 23.2\* | Consent of Cooley LLP (included in [Exhibit 5.1](d84517dex51.htm)). |  |  |  |  |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement).](#sig) |  |  |  |  |
| 99.1 | [Amended and Restated 2013 Equity Incentive Plan.](http://www.sec.gov/Archives/edgar/data/1598646/000119312525328715/d16725dex101.htm) | 8-K | 001-36517 | 10.1 | December 22, 2025 |
| 99.2 | [Form of Restricted Stock Unit Agreement under the Amended and Restated 2013 Equity Incentive Plan of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000119312516795845/d306566dex1001.htm) | 8-K | 001-36517 | 10.1 | December 16, 2016 |
| 99.3 | [Form of Option Grant Agreement under the Amended and Restated 2013 Equity Incentive Plan of the Registrant.](http://www.sec.gov/Archives/edgar/data/1598646/000156459017004048/nerv-ex1036_286.htm) | 10-K | 001-36517 | 10.36 | March 13, 2017 |
| 107\* | [Filing Fee Table.](d84517dexfilingfees.htm) |  |  |  |  |

---

\* Filed herewith

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, Commonwealth of Massachusetts, on December 23, 2025.

---

| | |
|:---|:---|
| **MINERVA NEUROSCIENCES, INC.** | **MINERVA NEUROSCIENCES, INC.** |
| By: | /s/ Remy Luthringer, Ph.D. |
|  | Remy Luthringer, Ph.D. |
|  | Chief Executive Officer<br> (Principal Executive Officer) |

---

**POWER OF ATTORNEY** 

**KNOW ALL PERSONS BY THESE PRESENTS**, that each person whose signature appears below constitutes and appoints Remy Luthringer, Geoffrey Race and Frederick Ahlholm, and each of them, as his true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Remy Luthringer, Ph.D.<br> Remy Luthringer, Ph.D. | Chief Executive Officer and Chairman of the Board<br> (*Principal Executive Officer*) | December 23, 2025 |
| /s/ Frederick Ahlholm<br> Frederick Ahlholm | Chief Financial Officer<br> (*Principal Financial Officer*) | December 23, 2025 |
| /s/ Hans Peter Hasler<br> Hans Peter Hasler | Member of the Board of Directors | December 23, 2025 |
| /s/ David Kupfer, M.D.<br> David Kupfer, M.D. | Member of the Board of Directors | December 23, 2025 |
| /s/ Fouzia Laghrissi-Thode, M.D.<br> Fouzia Laghrissi-Thode, M.D. | Member of the Board of Directors | December 23, 2025 |
| /s/ Jan van Heek<br> Jan van Heek | Member of the Board of Directors | December 23, 2025 |
| /s/ Inderjit Kaul, M.D.<br> Inderjit Kaul, M.D. | Member of the Board of Directors | December 23, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g84517dsp6.jpg)

Ryan S. Sansom

T: +1 617 937-2335

rsansom@cooley.com

December 23, 2025

Minerva Neurosciences, Inc.

1500 District Avenue

Burlington, MA 01803

**Re: Registration Statement on Form S-8** 

Ladies and Gentlemen:

We have acted as counsel to Minerva Neurosciences, Inc., a Delaware corporation (the "***Company***"), in connection with the filing by the Company of a Registration Statement on Form S-8 (the "***Registration Statement***") with the Securities and Exchange Commission (the "***Commission***") covering the offering by the Company of up to 13,200,000 shares (the "***Shares***") of its common stock, $0.0001 par value per share ("***Common Stock***") issuable pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended (the "***Plan***").

In connection with this opinion, we have examined and relied upon (a) the Registration Statement and the related prospectuses, (b) the Plan, (c) the Company's certificate of incorporation, and bylaws, each as currently in effect, and (d) such other records, documents, opinions, certificates, memoranda and instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plan, the Registration Statement and the related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

Cooley LLP 500 Boylston St, Boston, MA 02116

t: +1 (617) 937-2300 f: +1 (617) 937-2400 cooley.com

------

![LOGO](g84517dsp6.jpg)

December 23, 2025

Page Two

This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this opinion to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Sincerely,

---

| | |
|:---|:---|
| Cooley LLP | Cooley LLP |
| By: | /s/ Ryan S. Sansom |
|  | Ryan S. Sansom |

---

Cooley LLP 500 Boylston St, Boston, MA 02116

t: +1 (617) 937-2300 f: +1 (617) 937-2400 cooley.com

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated February 25, 2025, relating to the financial statements of Minerva Neurosciences, Inc. appearing in the Annual Report on Form 10-K of Minerva Neurosciences, Inc. for the year ended December 31, 2024.

/s/ Deloitte & Touche LLP

Boston, Massachusetts

December 23, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Minerva Neurosciences, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Stock, $0.0001 par value per share | Other | 667639 | $3.968 | $2649191.55 | 0.0001381 | $365.85 |
| 2 | Equity | Common Stock, $0.0001 par value per share | Other | 12532361 | $3.903 | $48913805.00 | 0.0001381 | $6755.00 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $51562996.55  |  | $7120.85  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $7120.85  |

---

 **Offering Note** <br>

<sup>1</sup> (A) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, par value $0.0001 per share ("Common Stock"), of Minerva Neurosciences, Inc. (the "Registrant") that become issuable under the Minerva Neurosciences, Inc. 2013 Equity Incentive Plan (the "2013 Plan") by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. (B) Represents 667,639 shares of Common Stock issuable upon the exercise of stock option awards previously granted under the 2013 Plan. (C) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The proposed maximum aggregate offering price per share and proposed maximum aggregate offering price were calculated using the weighted-average exercise price of $3.968 per share for such stock options.

<sup>2</sup> (A) Pursuant to Rule 416(a) under the Securities Act, this Registration Statement shall also cover any additional shares of Common Stock that become issuable under the 2013 Plan by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock. (B) Represents shares of Common Stock reserved for future issuance under the 2013 Plan, including 12,500,000 shares of Common Stock that were added to the shares reserved for future issuance under the 2013 Plan upon approval of an amendment to the 2013 Plan at the Registrant's 2025 Annual Meeting of Stockholders. (C) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rules 457(c) and (h) of the Securities Act. The proposed maximum aggregate offering price per share of $3.903 represents the average of the high and low prices of Common Stock, as reported on the Nasdaq Capital Market on December 18, 2025.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---